Plasma Kallikrein/KLKB1

Plasma Kallikrein/KLKB1 Molekülinformation

Englischer Name	Plasma kallikrein	Anzahl der inverkehr gebrachten Arzneimittel	4
Anzahl der klinischen Arzneimittel	13	Target-Alias	EC:3.4.21.34，EC 3.4.21，Fletcher factor，Plasma prekallikrein，KLKB1，Kallikrein B1，Kallikrein B， Plasma (Fletcher Factor) 1，Kininogenin，KLK3，PKK，Plasma Kallikrein，EC 3.4.21.34，PKKD，PPK，PKal，pKAL
Höchste Forschungs- und Entwicklungsphase	Approved

Englischer Name	Plasma kallikrein
Target-Alias	EC:3.4.21.34，EC 3.4.21，Fletcher factor，Plasma prekallikrein，KLKB1，Kallikrein B1，Kallikrein B， Plasma (Fletcher Factor) 1，Kininogenin，KLK3，PKK，Plasma Kallikrein，EC 3.4.21.34，PKKD，PPK，PKal，pKAL
Anzahl der inverkehr gebrachten Arzneimittel	4
Anzahl der klinischen Arzneimittel	13
Höchste Forschungs- und Entwicklungsphase	Approved

Plasma Kallikrein/KLKB1 Produktliste

Attribut
Protein (3)
Produktbibliothek
Online (3)
Spezies
Mouse (1)Human (1)Cynomolgus (1)
Etikett
His Tag (3)
Marker
Unconjugated (3)

Produktnummer	Spezies	Expressionssystem	Produktbeschreibung	Vorbestellen/Bestellen
KL1-H52H9	Human	HEK293	Human Plasma Kallikrein / KLKB1 Protein, His Tag (Pro-form, MALS verified)	In den Warenkorb legen
KL1-M52H9	Mouse	HEK293	Mouse Plasma Kallikrein / KLKB1 Protein, His Tag (active enzyme)	In den Warenkorb legen
KL1-C52H3	Cynomolgus	HEK293	Cynomolgus Plasma Kallikrein / KLKB1 Protein, His Tag (active enzyme, MALS verified)	In den Warenkorb legen

Gesamtmenge3

Plasma Kallikrein/KLKB1 Molekülhintergrund

Human Plasma Kallikrein, a serine protease, is synthesized in the liver and circulates in the plasma by binding to high molecular weight (HMW) kininogen or as a free zymogen. The enzyme cleaves Lys-Arg and Arg-Ser bonds. It activates, in a reciprocal reaction, factor XII after its binding to a negatively charged surface. It also releases bradykinin from HMW kininogen and may also play a role in the renin-angiotensin system by converting prorenin into renin.

Plasma Kallikrein/KLKB1 Molekülalias

Fletcher factor,kallikrein B, plasma (Fletcher factor) 1,kininogenin,KLK3 plasma kallikrein,KLKB1,plasma kallikrein heavy chain,plasma kallikrein light chain,Plasma Kallikrein,Plasma Prekallikrein,PPK,KLKB1

Klinische Arzneimittelinformation

Englischer Name	Forschungscode	Forschungsphase	Firma	Indikationen	Klinische Studie
Navenibart	QLS-215; STAR-0215	Phase 3 Clinical	Quellis Biosciences Inc	Angioedemas, Hereditary	Details
ADX-324	ADX-324; ADX324	Phase 3 Clinical	ADARx Pharmaceuticals Inc	Angioedemas, Hereditary	Details
Lonvoguran Ziclumeran	NTLA-2002	Phase 3 Clinical	Intellia Therapeutics Inc	Angioedemas, Hereditary	Details
THR-149	TG-758; THR-149	Phase 2 Clinical	Bicycle Therapeutics, Thrombogenics Inc	Diabetes Mellitus; Diabetic macular oedema; Diabetic Retinopathy	Details
BW-20805	BW-20805; BW20805	Phase 2 Clinical	Hangzhou Bolin Pharmaceutical Technology Co Ltd	Angioedemas, Hereditary	Details
MDPK-67b	DM-107; MDPK-67; MDPK-67b; MDKP 67b; RIK-7	Phase 1 Clinical	Med Discovery	Prostatic Neoplasms	Details
MSB-03	MSB-03	Phase 1 Clinical	MatriSys Bioscience Inc	Rosacea	Details
Avoralstat	BCX-V; BCX-4161	Phase 1 Clinical	Biocryst Pharmaceuticals Inc	Angioedemas, Hereditary; Diabetic macular oedema	Details
ADX-324(Tenacia)	ADX324; ADX-324	Phase 1 Clinical	Yuanyi Biotechnology (Shanghai) Co., Ltd.	Angioedemas, Hereditary	Details
ZKLJ-02		Phase 1 Clinical	Kunming Longjin Pharmaceutical Co Ltd	Cardiovascular Diseases; Ischemic Stroke; Nervous System Diseases; Stroke	Details
ATN-249	ATN-249	Phase 1 Clinical	Attune Pharmaceuticals	Angioedemas, Hereditary	Details
BI-Z		Clinical	Boehringer Ingelheim Pharma Gmbh & Co Kg	Wet Macular Degeneration	Details
mRNA encoded Cas9 targeting human KLKB 1 gene therapy (Pharma Gateway)		Clinical	Pharma Gateway AB	Angioedemas, Hereditary	Details

Inverkehr gebrachte Arzneimittelinformation

Englischer Name	Forschungscode	Forschungsphase	Firma	Frühestes Markenname	Frühestes Genehmigungsland	Früheste Indikation	Früheste Genehmigungsgesellschaft	Früheste Genehmigungsdatum	Indikationen	Klinische Studie
Lanadelumab	2372V1TKXK (UNII code); X124-G01; SHP-643; DX-2930; TAK-743	Approved	Dyax Pharma	Takhzyro, 达泽优	United States	Angioedemas, Hereditary	Dyax Corp	2018-08-23	Angioedema; Angioedemas, Hereditary; Coronavirus Disease 2019 (COVID-19); Hereditary Autoinflammatory Diseases; Lung Injury	Details
Berotralstat	BCX-7353	Approved	Biocryst Pharmaceuticals Inc	ORLADEYO	United States	Angioedemas, Hereditary	Biocryst Pharmaceuticals Inc	2020-12-03	Angioedemas, Hereditary	Details
Ecallantide	DX-88; EPI-KAL2; FOV-2302; CB-500929	Approved	Dyax Pharma	Kalbitor	United States	Angioedema	Dyax Corp	2009-12-01	Angioedema; Angioedemas, Hereditary; Blood Loss, Surgical; Hemorrhage; Hereditary Angioedema Types I and II; Macular Edema; Retinal Vein Occlusion	Details
Sebetralstat	KVD-900	Approved	Vantia Therapeutics Ltd.	Ekterly	United States	Angioedemas, Hereditary	Kalvista Pharmaceuticals Ltd, Kalvista Pharmaceuticals Inc	2025-07-03	Angioedemas, Hereditary	Details